StoxAkums Drugs and Pharmaceuticals Limited
NSE: AKUMS · Healthcare
Ask the data
Instant answers about Akums Drugs and Pharmaceuticals Limited — computed from its filings, no language modelPrice & valuation
split & bonus adjusted · pick a metric and rangeAnnual performance
annual · ₹ crore · line = operating margin| FY26 | |
|---|---|
| Revenue | 4,359 |
| EBITDA | 522 |
| Operating margin | 12.0% |
| Interest | 94 |
| Depreciation | 155 |
| Profit before tax | 382 |
| Tax | 126 |
| Net profit | 255 |
| EPS ₹ | 16.67 |
| Operating cash flow | 1,181 |
| Capex | 231 |
| Dividend paid | 0 |
| Total assets | 5,447 |
| Equity | 3,313 |
Quarterly performance
last 9 quarters · ₹ crore| JUN '24 | SEP '24 | DEC '24 | JUN '25 | SEP '25 | DEC '25 | MAR '26 | JUN '26 | SEP '26 | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1,019 | 1,033 | 1,010 | 1,024 | 1,018 | 1,160 | 1,158 | 1,167 | 1,342 |
| Operating profit | 128 | 121 | 121 | 129 | 94 | 147 | 152 | 175 | 195 |
| Operating margin | 12.6% | 11.7% | 12.0% | 12.6% | 9.3% | 12.7% | 13.1% | 15.0% | 14.5% |
| Other income | 7 | 13 | 15 | 27 | 32 | 34 | 35 | 30 | 29 |
| Interest | 13 | 12 | 5 | 23 | 23 | 24 | 24 | 25 | 26 |
| Depreciation | 34 | 35 | 45 | 37 | 38 | 40 | 40 | 41 | 43 |
| Profit before tax | 87 | 92 | 91 | 96 | 66 | 100 | 121 | 139 | 155 |
| Tax | 26 | 25 | 25 | 31 | 23 | 32 | 40 | 38 | 40 |
| Net profit | 60 | 65 | 65 | 63 | 41 | 66 | 85 | 100 | 113 |
| EPS ₹ | 4.21 | 4.37 | 4.26 | 4.15 | 2.66 | 4.33 | 5.53 | 6.53 | 7.37 |
| Revenue YoY | — | — | — | 0.5% | -1.5% | 14.8% | — | 13.9% | 31.9% |
| Profit YoY | — | — | — | 5.5% | -37.5% | 1.7% | — | 57.5% | 176.7% |
Returns & margins
trailing-twelve-month, per quarter| MAR '26 | JUN '26 | SEP '26 | |
|---|---|---|---|
| ROE | 7.7% | 8.8% | 10.4% |
| ROCE | 14.1% | 15.4% | 17.3% |
| Net margin | 5.9% | 6.5% | 7.5% |
| EBITDA margin | 12.0% | 12.6% | 13.8% |
| Debt / equity | 0.02 | 0.02 | 0.01 |
| Interest coverage | 5.06 | 5.45 | 6.25 |
| Asset turnover | 0.80 | 0.83 | 0.83 |
Balance sheet
equity vs borrowings over time · ₹ crore| SEP '24 | SEP '25 | MAR '26 | SEP '26 | |
|---|---|---|---|---|
| Share capital | 31 | 31 | 31 | 31 |
| Other equity / reserves | 2,803 | 3,118 | 3,283 | 3,472 |
| Total equity | 2,833 | 3,149 | 3,313 | 3,503 |
| Borrowings | 459 | 10 | 73 | 36 |
| Current liabilities | 1,233 | 833 | 1,095 | 1,266 |
| Non-current liabilities | 191 | 1,158 | 1,021 | 1,043 |
| Total assets | 4,270 | 5,159 | 5,447 | 5,832 |
| Property, plant & equipment | 1,249 | 1,243 | 1,448 | 1,523 |
| Capital work-in-progress | 164 | 158 | 177 | 246 |
| Investments | 0 | 0 | 0 | 71 |
| Inventories | 660 | 648 | 756 | 903 |
| Receivables | 949 | 746 | 797 | 859 |
| Cash & equivalents | 482 | 229 | 386 | 184 |
Cash flow
annual · ₹ crore · line = free cash flow| FY26 | |
|---|---|
| Cash from operations | 1,181 |
| Cash from investing | -930 |
| Cash from financing | 34 |
| Capex | 231 |
| Free cash flow | 951 |
| Dividends paid | 0 |
Where the assets sit
Sep '26 · ₹ crorePeer comparison
largest in Healthcare · this company in bold| Company | Market cap ₹cr | Price | P/E | P/B | ROE |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 4,46,270 | 1,860.00 | 40.7 | 5.00 | 12.3% |
| Divi's Laboratories Ltd. | 2,73,493 | 10,320.50 | 93.5 | 16.32 | 17.5% |
| Torrent Pharmaceuticals Ltd. | 1,80,671 | 4,750.00 | 85.1 | 9.83 | 11.6% |
| Laurus Labs Ltd. | 1,26,430 | 2,340.00 | 94.4 | 20.86 | 22.1% |
| Apollo Hospitals Enterprise Ltd. | 1,21,453 | 8,446.00 | 54.2 | 11.45 | 21.1% |
| Zydus Lifesciences Ltd. | 1,19,550 | 1,197.90 | 28.6 | 4.30 | 15.0% |
| Dr. Reddy's Laboratories Ltd. | 1,14,646 | 1,373.00 | 40.9 | 2.95 | 7.2% |
| Cipla Ltd. | 1,13,988 | 1,411.00 | 39.3 | 3.22 | 8.2% |
| Mankind Pharma Ltd. | 1,04,902 | 2,540.00 | 46.7 | 5.97 | 12.8% |
| Aurobindo Pharma Ltd. | 1,03,572 | 1,800.00 | 26.0 | 2.63 | 10.1% |
| Akums Drugs and Pharmaceuticals Limited | 11,252 | 734.95 | 30.9 | 3.21 | 10.4% |
StoxGud checklist: Bullish setup · 7/10
- Price above 50-day average
- Price above 200-day average
- 50-day average above 200-day (uptrend)
- RSI in healthy 40–70 zone
- Positive 1-year return
- Return on equity above 15%
- Debt to equity below 1
- Revenue growing year on year
- Net profit margin above 10%
- P/E below industry median
A rules-based screen of trend, momentum, quality and valuation. Educational only — not a buy or sell recommendation.
Returns & technicals
FAQs
What is the share price of Akums Drugs and Pharmaceuticals Limited?
Akums Drugs and Pharmaceuticals Limited (AKUMS) closed at ₹734.95 on NSE on 06 Nov 2026.
What is the market cap of Akums Drugs and Pharmaceuticals Limited?
₹11,252 crore at the latest close.
What is the P/E ratio of Akums Drugs and Pharmaceuticals Limited?
30.9, on trailing-twelve-month earnings from its filings.
How fast is Akums Drugs and Pharmaceuticals Limited growing?
Akums Drugs and Pharmaceuticals Limited: Latest-quarter revenue is up 31.9% year on year, profit up 176.7%.
How profitable is Akums Drugs and Pharmaceuticals Limited?
On a trailing-twelve-month basis return on equity is 10.4%, return on capital employed 17.3%, operating margin 13.8%, net margin 7.5%.
How much debt does Akums Drugs and Pharmaceuticals Limited have?
Akums Drugs and Pharmaceuticals Limited is debt-free: debt to equity is 0.01 with borrowings of ₹36 cr against cash of ₹184 cr (balance sheet of 2026-09-30). Operating profit covers interest 6.2 times.
Financials parsed from Akums Drugs and Pharmaceuticals Limited's own XBRL filings to NSE (consolidated), ₹ crore unless marked. Quarterly from JUN '24, annual from FY26, balance sheet from Sep '24. * = derived (full year or half year minus earlier quarters). Information only, not investment advice.